A Randomized Controlled Study of BAY 43-9006 [sorafenib] in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2014
At a glance
- Drugs Sorafenib (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 12 Jul 2011 Additional trial location ( United Kingdom) identified as reported by EudraCT.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
- 17 Nov 2010 Results published in the the Journal of the American Medical Association
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History